Phytotherapy (BNO 1045) of Acute Lower Uncomplicated Urinary Tract Infection in Women Normalizes Local Host Responses.
BNO 1045
Phytotherapy
Uncomplicated urinary tract infection
Urine cytokines
Journal
Urologia internationalis
ISSN: 1423-0399
Titre abrégé: Urol Int
Pays: Switzerland
ID NLM: 0417373
Informations de publication
Date de publication:
2023
2023
Historique:
received:
14
12
2022
accepted:
13
05
2023
medline:
12
9
2023
pubmed:
7
8
2023
entrez:
6
8
2023
Statut:
ppublish
Résumé
Acute lower uncomplicated urinary tract infection (uUTI) affects a large proportion of women. Increased antimicrobial resistance has created an urgent need for novel therapeutics and the phytotherapeutic drug BNO 1045 (Canephron® N) has previously been shown to be noninferior to standard antimicrobial stewardship. This sub-analysis from a randomized, double-blind, controlled phase III noninferiority clinical trial using BNO 1045 versus fosfomycin to treat uUTI aimed to determine how urine cytokine levels are altered by the two different treatments. Urine samples from a predefined subset of women diagnosed with uUTI (18-70 years) and treated with BNO 1045 (n = 58) or fosfomycin (n = 69) were analyzed for urine levels of IL-6 and IL-8, using analyte-to-creatinine ratios. BNO 1045 treatment showed similar effects to fosfomycin treatment in reducing both urine IL-6 and IL-8 levels. Mean IL-6 and IL-8 levels were markedly reduced in all patients regardless of treatment. BNO 1045 treatment decreased urine IL-8 significantly (p = 0.0142) and showed a trend toward reduction of urine IL-6 (p = 0.0551). Fosfomycin treatment reduced both IL-6 and IL-8 levels significantly (p = 0.0038, <0.0001 respectively). BNO 1045 is, in addition to reducing symptoms, comparable to fosfomycin treatment in reducing the local inflammatory response associated with uUTI.
Identifiants
pubmed: 37544300
pii: 000531206
doi: 10.1159/000531206
pmc: PMC10614491
doi:
Substances chimiques
canephron N
0
Fosfomycin
2N81MY12TE
Interleukin-8
0
Interleukin-6
0
Anti-Bacterial Agents
0
Types de publication
Randomized Controlled Trial
Clinical Trial, Phase III
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
778-784Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Références
J Leukoc Biol. 1994 Nov;56(5):559-64
pubmed: 7964163
Br J Gen Pract. 2002 Sep;52(482):729-34
pubmed: 12236276
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Front Physiol. 2022 Jul 04;13:886782
pubmed: 35860658
PLoS Med. 2018 May 15;15(5):e1002569
pubmed: 29763434
Clin Infect Dis. 2012 Sep;55(6):771-7
pubmed: 22677710
Scand J Infect Dis. 2004;36(4):296-301
pubmed: 15198188
Antibiotics (Basel). 2021 Jun 08;10(6):
pubmed: 34201264
J Urol. 2017 Jul;198(1):107-115
pubmed: 28161350
Urol Int. 2018;101(3):327-336
pubmed: 30231252
Infect Immun. 1993 Feb;61(2):602-9
pubmed: 8423089
Ger Med Sci. 2016 Feb 10;14:Doc01
pubmed: 26909012
Infect Immun. 1993 Apr;61(4):1307-14
pubmed: 8454332
Biochem J. 1990 Feb 1;265(3):621-36
pubmed: 1689567
PLoS Pathog. 2016 Oct 12;12(10):e1005848
pubmed: 27732661
JCI Insight. 2019 May 30;5:
pubmed: 31145099
BMJ. 2017 Nov 7;359:j4784
pubmed: 29113968
Eur Urol. 2017 Dec;72(6):865-868
pubmed: 28754533
Phytomedicine. 2019 Jul;60:152987
pubmed: 31257118
Int J Urol. 2016 Feb;23(2):168-74
pubmed: 26552369
J Ethnopharmacol. 2000 Aug;71(3):465-72
pubmed: 10940584
EBioMedicine. 2014 Oct 24;1(1):46-57
pubmed: 26125048
J Clin Invest. 1993 Aug;92(2):780-5
pubmed: 8349817
BMJ. 2015 Dec 23;351:h6544
pubmed: 26698878